Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hayman

Showing results (341-350 of 446) with videos related to

Pageof 45
Sort By:
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Haematologica|November 2, 2020
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitorYucai Wang, Kari G Rabe, Michael S Bold, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Pageof 45

Showing results (341-350 of 446) with videos related to

Sort By:
Pageof 45
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Haematologica|November 2, 2020
The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitorYucai Wang, Kari G Rabe, Michael S Bold, et al.
Leukemia|July 27, 2016
Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progressionW I Gonsalves, S V Rajkumar, A Dispenzieri, et al.
European Journal of Haematology|November 24, 2020
Characterization and prognostic implication of delayed complete response in AL amyloidosisEli Muchtar, Morie A Gertz, Shaji K Kumar, et al.
American Journal of Hematology|July 19, 2020
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratioEli Muchtar, Morie A Gertz, Martha Q Lacy, et al.
American Journal of Hematology|October 4, 2025
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple MyelomaAbiola Bolarinwa, Saurabh Zanwar, Nadine Abdallah, et al.
Blood Advances|January 30, 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomesCharalampos Charalampous, Jean-Sebastien Claveau, Prashant Kapoor, et al.
JCO Oncology Practice|May 30, 2025
Erratum: Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource UtilizationJenna R Puttkammer, Jason N Barreto, Chelsee J Jensen, et al.
Mayo Clinic Proceedings|February 17, 2019
A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified TypingEli Muchtar, Morie A Gertz, Robert A Kyle, et al.
Pageof 45